GlassScriptPhysician profile
Chang Ho Suk
NPI 1447316104
$59,822.61
in general payments reported to CMS, 2019-2025
16 companies · $7,082 in 2025
The $7,082 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,446 · 2020: $4,824 · 2021: $8,753 · 2022: $8,949 · 2023: $14K · 2024: $10K · 2025: $7,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $3,532 · Travel and Lodging: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,760.00 |
| Food and Beverage | $3,531.55 |
| Travel and Lodging | $558.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $54,063.70 | 2019-2025 | Vemlidy |
| Amgen INC. | $1,839.81 | 2019-2025 | Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $639.88 | 2020-2023 | Tagrisso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $625.00 | 2019-2024 | Jardiance |
| Abbvie INC. | $515.48 | 2019-2022 | |
| Novo Nordisk INC | $497.56 | 2021-2025 | Ozempic |
| Phathom Pharmaceuticals, INC. | $384.18 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $245.46 | 2022-2025 | Ibsrela |
| Amarin Pharma, INC. | $242.74 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $204.81 | 2020-2022 | |
| Allergan, INC. | $129.65 | 2019 | |
| Exact Sciences Corporation | $119.81 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $113.51 | 2019 | |
| Merck Sharp & Dohme LLC | $81.95 | 2019 | |
| Madrigal Pharmaceuticals | $76.65 | 2024-2025 | Resmetirom, Rezdiffra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $42.42 | 2023 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chang Ho Suk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.